Treatment of uremic bone disease action of 5,6-trans-25-hydroxycholecalciferol (a vitamin D-analog) in chronic renal failure

1973 ◽  
Vol 51 (19) ◽  
pp. 979-981 ◽  
Author(s):  
D. Herrath ◽  
K. Schaefer ◽  
D. Kraft ◽  
H. -G. Grigoleit ◽  
P. Koeppe
2015 ◽  
Vol 21 (3) ◽  
pp. 887-890 ◽  
Author(s):  
Bistra T. Galunska ◽  
◽  
Daniela I. Gerova ◽  
Dobrin N. Paskalev ◽  
Rositza Y. Zorcheva ◽  
...  

1985 ◽  
Vol 31 (11) ◽  
pp. 1815-1819 ◽  
Author(s):  
B W Hollis ◽  
J L Napoli

Abstract We describe a faster, more-sensitive radioimmunoassay for vitamin D in plasma. Antibodies were generated in rabbits immunized with a new vitamin D analog, the 23,24,25,26,27-pentanor-C(22)-carboxylic acid of vitamin D, coupled directly with bovine serum albumin. After several months, Rivanol-treated sera from the rabbits contained high-titer antibodies, as determined by their abilities to bind 25-hydroxy-[3H]cholecalciferol. The antibody, used at a 1:15 000 final dilution, cross reacted equally with all cholecalciferol and ergocalciferol metabolites tested except 1,25-dihydroxycalciferol metabolites and the parent calciferols. 25-Hydroxycalciferol and similar forms were efficiently extracted from plasma or serum with acetonitrile. We separated bound from free 25-hydroxy-[3H]cholecalciferol by using a second antibody: goat antiserum to rabbit serum. The detection limit of the assay was 3.0 pg of 25-hydroxycholecalciferol and its equivalents per tube; thus only 1 microL of plasma is needed per assay tube. Results compared well with those from a liquid-chromatographic procedure involving specific ultraviolet detection of 25-hydroxycalciferol in plasma.


1997 ◽  
Vol 7 (S3) ◽  
pp. 202-208 ◽  
Author(s):  
E. Slatopolsky ◽  
A. J. Brown

The Lancet ◽  
1975 ◽  
Vol 305 (7916) ◽  
pp. 1147
Author(s):  
C.E. Dent ◽  
Mercedes Domenech ◽  
J.M. Gertner

Sign in / Sign up

Export Citation Format

Share Document